NCT00284921View on ClinicalTrials.gov

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

PHASE3TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2006

Conditions
De Novo Kidney Transplant
Interventions
DRUG

Enteric-coated Mycophenolate sodium (EC-MPS)

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00284921 - MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive | Biotech Hunter | Biotech Hunter